dinoprost and Puerperal-Disorders

Topics: Dinoprost; Dinoprostone; Female; Humans; Menstruation-Inducing Agents; Pregnancy; Puerperal Disorders; Uterine Inertia

Topics: Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Female; Humans; Postpartum Hemorrhage; Pregnancy; Prostaglandins; Prostaglandins E, Synthetic; Prostaglandins F, Synthetic; Puerperal Disorders; Uterine Inertia

Postpartum atony with haemorrhage is a life-threatening condition which may necessitate surgical intervention with ligation of the ascending arterial branches or hysterectomy. On the basis of the literature, recent medical treatment with the prostaglandins F2 alpha and E2 is reviewed. When this treatment was employed, surgical intervention could be avoided in 60-100% of the cases which did not respond to ordinary treatment for atony. The forms of administration, which may be intravenous, intramuscular, intravaginal or injection into the myometrium, are discussed. In addition, the dosage, choice of prostaglandin and the contraindications of treatment are reviewed. It is concluded that prostaglandin treatment should be considered prior to surgical treatment and that the possibilities of obtaining prostaglandin rapidly should be present in all maternity departments.

Topics: Dinoprost; Dinoprostone; Female; Humans; Pregnancy; Puerperal Disorders; Uterine Contraction; Uterine Hemorrhage

The objective of this study was to evaluate the effects of early postpartum PGF two alpha treatment on reproductive performance in dairy cows with calving and puerperal traits. A total of 363 Holstein cows (128 primiparous and 235 multiparous) were selected based on the presence of at least one of calving and puerperal traits (dystocia, retained placenta, twin, abortion, and postpartum uterine infections) and were assigned to two groups (treatment and control) irrespective of presence or absence of luteal tissue. Cows in the treatment group were treated twice with 25 mg dinoprost 8 h apart on day 20 postpartum, and for the control group saline placebo was administered. As it was speculated that the timing of a second dose would mimic the release of endogenous PGF2α from the uterus, our hypothesis was that two doses of PGF2α 8 h apart may increase the duration of elevated plasma prostaglandin F2α metabolite concentration in these cows. Recorded reproductive variables included days to first estrus, days to first AI, first service conception rate, pregnancy by 150 days in milk, service per conception, open days, and the percentage of repeat breeder animals. The data were analyzed using SPSS (Version 15) (IBM North America, New York, NY, USA) and Minitab (Version 14) (Minitab, State College, PA, USA). Although early postpartum PGF2α treatment had no effect on days to first estrus (36.7 days vs. 34.9 days, P = 0.056) and days to first AI (70.5 days vs. 72.2 days, P = 0.537), it increased first service conception rate (47.1% vs. 27.6%, P < 0.001); and this was more remarkable in primiparous cows (64.7% vs. 25%, P < 0.001). PGF2α treatment reduced the mean service per conception (1.92 vs. 2.72, P < 0.001) and the mean open days (112 days vs. 144 days, P < 0.001), and increased pregnancy by 150 days in milk (DIM) (80% vs. 66%, P = 0.004). The prevalence of repeat breeder syndrome in cows with calving and puerperal traits was reduced by PGF2α treatment (10% vs. 29.8%, P < 0.001). In conclusion, treatment of cows with calving and puerperal traits twice with a luteolytic dose of PGF2α 8 h apart on Day 20 postpartum improved reproductive performance and reduced the prevalence of repeat breeder syndrome.

Topics: Animals; Cattle; Cattle Diseases; Dairying; Dinoprost; Female; Oxytocics; Postpartum Period; Prevalence; Puerperal Disorders; Reproduction

The objective was to evaluate the effect of 2 doses of PGF(2alpha) injected early postpartum on uterine involution, serum concentration of acute phase proteins at 12 d postpartum, and fertility in Holstein cows with acute puerperal metritis. Only cows diagnosed with retained fetal membranes and metritis and treated with ceftiofur hydrochloride for 5 d were used in the study. Two hundred cows were assigned randomly to be treated (n = 100) or to serve as controls (n = 100). Treatment consisted of 2 i.m. injections of PGF(2alpha) 8 h apart on d 8 postpartum. A subsample of 90 cows was selected randomly (45 treated cows; 45 controls) to evaluate uterine diameter using ultrasonography, uterine score, and serum concentrations of acute phase proteins at 12 d postpartum. The outcome variable for all cows was conception rate at first service. Postpartum, primiparous, treated cows had smaller uterine diameters and lower uterine scores than controls. Cows with a uterine diameter <5.1 cm at 12 d postpartum were 5.5 times more likely to conceive at first service than cows with larger uterine horn diameter. Treatment significantly reduced the concentrations of serum alpha1-acid glycoprotein. Within primiparous cows, treatment also increased conception at first service by 17%. It was concluded that 2 doses of PGF(2alpha) 8 h apart at 8 d postpartum in primiparous cows with acute puerperal metritis decreased the diameter of uterine horns and serum concentration of alpha1-acid glycoprotein at 12 d postpartum and increased the conception rate at first service.

Topics: Acute Disease; Acute-Phase Proteins; Animals; Cattle; Cattle Diseases; Dinoprost; Endometritis; Female; Fertility; Orosomucoid; Puerperal Disorders; Treatment Outcome; Ultrasonography; Uterus

Moxibustion on 12 specific points (Keiketsu in Japanese) was applied for treatment of delayed uterine involution in 16 cows that were diagnosed on the basis of rectal palpation and vaginoscopic examination 21 to 35 days after parturition. The treatment was continued for three consecutive days. Other 32 cows with the delayed uterine involution were either injected intramuscularly with 25 mg PGF2 alpha (17 cows) or infused in utero with 500 mg ampicillin (15 cows). The uterine involution following the treatment was monitored by rectal palpation and vaginoscopic examination. Milk samples were collected three times weekly and used for milk progesterone assay to monitor the ovarian function. No significant difference was observed in the uterine involution among the groups treated with moxibustion, PGF2 alpha or ampicillin. Percentages of cows with abnormal cervical mucus and bacterial isolation from cervical swab decreased remarkably in all groups during 4 weeks after treatment. Forty-six percent of cows with delayed uterine involution was diagnosed as having inactive ovaries. Percentage of cows that responded with ovulation and corpus luteum formation after moxibustion was 67 percent, slightly higher than those in cows treated with PGF2 alpha or ampicillin. Reproductive performance after the moxibustion was well-comparable to those after PGF2 alpha or ampicillin treatment. Result indicates that the moxibustion could be used as the alternative to PGF2 alpha and antibiotics for treating delayed uterine involution in cows.

Topics: Administration, Topical; Ampicillin; Animals; Cattle; Cattle Diseases; Dinoprost; Female; Milk; Moxibustion; Ovary; Pregnancy; Progesterone; Puerperal Disorders; Uterine Diseases; Uterus

The objective of this study was to investigate the effects of puerperal uterine disease on uterine blood flow using trans-rectal Doppler sonography. Lactating Holstein Friesian cows (n=44) were divided into two groups based on whether they were healthy (UD-; n=23) or had uterine disease (UD+; n=21) defined as retained fetal membranes and/or metritis. General clinical examination, vaginoscopy, trans-rectal palpation, and trans-rectal B-Mode sonography were conducted on Days 8, 11, 18, 25 and then every 10 days until Day 65 after calving. Doppler sonography of the uterine arteries was conducted on Day 8, during diestrus after the second ovulation (Days 40-60 after calving) and during diestrus before breeding (Days 63-75 after calving). Cows with uterine disease had greater (P<0.05) uterine size as assessed trans-rectally compared with cows of the UD group. Sonographic measurements on Day 11 after parturition revealed a greater (P<0.05) horn diameter in cows of the UD+ than in the UD- group. Both uterine size and uterine horn diameter decreased more earlier following parturition (P<0.05) in cows of the UD- group. Blood flow volume (BFV) was greater and pulsatility index was less on Day 8 after calving in cows of UD+ than UD- group (P<0.05). In cows of the UD-, but not in those of the UD+ group, there was a further reduction in BFV subsequent to Day 45 after calving (P<0.05). The results of this study show that uterine blood flow measures by trans-rectal Doppler sonography are affected by puerperal uterine disease.

Topics: Animals; Cattle; Cattle Diseases; Dairying; Dinoprost; Female; Puerperal Disorders; Regional Blood Flow; Ultrasonography, Doppler; Uterine Artery; Uterine Diseases; Uterus

Topics: Animals; Cattle; Cattle Diseases; Dinoprost; Fatty Acids, Nonesterified; Female; Hydrocortisone; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Ovarian Cysts; Parity; Pregnancy; Puerperal Disorders

The objective of the present study was to validate a simple, sensitive and direct enzymeimmunoassay (EIA) procedure for 13,14-dihydro-15-keto-PGF(2alpha) (PGFM) for use in buffaloes with postpartum reproductive disorders and determine the practicalities of using plasma concentrations of 13,14-dihydro-15-keto-PGF(2alpha) for monitoring their reproductive health. The EIA was used for determination of the circulating levels of PGFM associated with the retention of fetal membranes, postpartum endometritis and variable postpartum intervals. The concentrations of PGFM with retention of fetal membranes in the periparturient period were lower as compared to buffaloes that had uneventful parturitions. Concentrations of PGFM associated with postpartum endometritis were elevated as compared to those in buffaloes free of reproductive tract infections. Buffaloes having higher plasma concentrations of PGFM in early postpartum period had shorter postpartum intervals, indicating the association between PGFM concentrations postpartum and uterine involution as well as the resumption of estrous cycle in this species. The study presents the possibility of using circulating PGFM concentrations for monitoring the postpartum reproductive health of buffaloes.

Topics: Animals; Antibody Specificity; Buffaloes; Dinoprost; Endometritis; Female; Immunoenzyme Techniques; Placenta, Retained; Postpartum Period; Pregnancy; Puerperal Disorders; Reproducibility of Results; Reproduction; Sensitivity and Specificity; Uterine Diseases

The investigations were carried out on a total of 70 cows with puerperal endometritis. In addition to intrauterine antibiotic treatment, 30 experimental animals were administered 20 microg GnRH analogue, buserelin, between days 10 and 12 post-partum followed by 500 microg PGF2alpha analogue, cloprostenol, 10 days later. Forty control cows were treated only with intrauterine antibiotics. Blood samples for progesterone determination were collected from the tail vein twice weekly until day 70 post-partum. The first rise in progesterone level above 3.18 nmol/l occurred significantly earlier in the experimental than in control cows (21.6 +/- 9.2 versus 27.8 +/- 12.3 days; p < or = 0.05). The duration of the first cycle post-partum was 15.0 +/- 4.3 days in experimental and 19.7 +/- 7.3 days in control animals (p < or = 0.05). However, no significant differences were observed in the occurrence of first oestrus post-partum. The involution of the uterus was improved after hormone treatment. At day 42 post-partum, completion of uterine involution was found in 93.3% of hormone-treated cows and in 82.5% of those treated with antibiotic only (p < or = 0.05). Clinical recovery was 96.6% in the experimental and 82.5% in the control group (p < or = 0.05). First service pregnancy rate was significantly better in hormone-treated than control cows (51.7 versus 36.4%; p < or = 0.05). Total pregnancy rate and insemination index values were not significantly improved following GnRH and PGF2alpha treatment. The average service period was 89.8 +/- 21.2 days in cows after hormone treatment, and 112.6 +/- 24.5 days in control cows. The difference was statistically significant (p < or = 0.05). These results indicate, that the sequential GnRH and PGF2alpha application in cows with puerperal endometritis positively affected ovarian function and uterine involution, resulting in improved fertility performance.

Topics: Animals; Buserelin; Cattle; Cattle Diseases; Cloprostenol; Dairying; Dinoprost; Drug Administration Schedule; Drug Therapy, Combination; Endometritis; Erythromycin; Female; Fertility; Fertility Agents, Female; Progesterone; Puerperal Disorders; Tetracycline

The effect of mimicking prepartum concentration of estradiol-17 beta on the inflammatory response to endotoxin in gilts was studied. The study was performed in a split-litter design and comprised 5 pairs of littermates. A catheter was inserted into the jugular vein 2 days prior to the start of the study. In each pair, 1 littermate was treated IM with 2.5 mg of estradiol-17 beta/75 kg of body weight, and the other littermate was given peanut oil IM as a control. The day after treatment, all gilts were challenge-exposed with a Salmonella typhimurium-derived endotoxin (1 microgram/kg, IV) and the inflammatory response to challenge exposure was monitored. There was no effect of estradiol treatment on the transient clinical signs of endotoxemia or on the increase in rectal temperature. The increase in blood concentrations of prostaglandin F2 alpha metabolite and cortisol after endotoxin challenge exposure was not affected by estradiol. Decrease in number of circulating blood mononuclear cells and polymorphonuclear leukocytes was not changed by estradiol treatment. Taken together, mimicking prepartum concentration of estradiol did not affect either the magnitude or the kinetics of the inflammatory response to endotoxin in gilts. Relevance of these findings to development of endotoxin-mediated diseases, such as the postpartum agalactia syndrome, needs further study.

Topics: Animals; Dinoprost; Endotoxins; Estradiol; Female; Hydrocortisone; Inflammation; Pregnancy; Puerperal Disorders; Swine; Swine Diseases; Syndrome; Toxemia

Topics: Contraindications; Dinoprost; Female; Humans; Pregnancy; Puerperal Disorders; Uterine Inertia

Platelet prostaglandin (PG) E and plasma PGF2 alpha concentrations were measured by radioimmunoassay methods and compared in non-pregnant and pregnant, normal and diabetic subjects. The blood samples were obtained in the follicular phase in the non-pregnant women and in the third trimester and after delivery in the pregnant women. The immunoreactive platelet PGE (IRPGE) levels were significantly higher in the pregnant diabetic women than in the normal non-pregnant and pregnant women and diabetic non-pregnant women. The immunoreactive plasma PGF2 alpha (IRPGF2 alpha) concentrations were significantly higher in the non-pregnant diabetic women than in the normal non-pregnant and pregnant women. During pregnancy, the plasma IRPGF2 alpha were further increased significantly in the diabetic subjects compared to the non-pregnant diabetics. Both the platelet IRPGE and plasma IRPGF2 alpha concentrations were higher in the pregnant diabetic subjects with retinopathy than in those without retinopathy. These findings suggest that pregnancy and diabetes influence the synthesis of PGE and PGF2 alpha in the platelets and plasma, respectively. The increased production of these prostaglandins are possible exacerbating factors of diabetic retinopathy during pregnancy.

Topics: Adult; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dinoprost; Female; Humans; Postpartum Period; Pregnancy; Pregnancy in Diabetics; Pregnancy Trimester, Third; Prostaglandins E; Puerperal Disorders; Reference Values

Carprofen, a non-steroidal anti-inflammatory drug (NSAID) known to inhibit prostaglandin synthesis, was given intravenously in five cows at a daily dose of 0.7 mg/kg for five days beginning on day 1 postpartum. Blood samples were collected at various times over a period of six days following the first injection. At this dose, carprofen reached highest plasma values of about 45 micrograms/ml after the fifth injection and was well tolerated by all the cows. During the whole experimental period, mean plasma levels of 15-keto-13, 14-dihydro-prostaglandin F2 alpha, the primary metabolite of PGF2 alpha, were significantly (p less than 0.05) lower in treated than in control animals (28-47% vs 64-101% of pretreatment concentrations). The suppressive effect of carprofen on PGF2 alpha-production occurred immediately after its application and was maximal 3-6 h post injection on the first and on the fifth experimental day (60-80% and 40-85%, respectively). We conclude from our results that carprofen in a single dose of 0.7 mg/kg b.w. effectively suppresses PGF2 alpha-release in the postpartum cow. Whether this effect is beneficial in the treatment of uterine inflammatory processes remains to be determined.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cattle; Cattle Diseases; Dinoprost; Endometritis; Female; Pregnancy; Puerperal Disorders

The aim of this work was to investigate possible differences in peripheral blood concentrations of 13, 14 dihydro 15 keto PGF alpha (PGFM) and 6 keto PGF1 alpha (PGIM), between dairy cows retaining (RP) and not retaining (NRP) their placenta. Blood samples were collected 5, 30, and 60 minutes postpartum from 8 RP and 17 NRP cows. PGFM concentrations were significantly lower in RP cows than in NRP cows 60 minutes after birth (8156 pg/ml vs 12016 pg/ml; P less than or equal to 0.05). There was a significant rise of PGFM levels between 30 and 60 minutes in NRP cows (6225 pg/ml vs 12016 pg/ml; P less than or equal to 0.01), while in RP cows PGFM levels remained fairly constant along the period studied. No significant differences were found between RP and NRP cows regarding PGIM levels during this period although absolute values were slightly higher in RP cows. The PGFM/PGIM ratio was significantly higher 60 minutes postpartum in NRP cows than in RP cows (15.5 vs 8.8; P less than or equal to 0.01). This ratio increased significantly in NRP cows between 30 and 60 minutes (7.2 vs 15.5; P less than or equal to 0.01), a pattern not observed in RP cows. There was no correlation between PGIM and PGFM levels during the first 60 minutes postpartum in the NRP cows. However, the same correlation was significantly positive in the RP cows (r = 0.75; P less than or equal to 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: 6-Ketoprostaglandin F1 alpha; Animals; Cattle; Cattle Diseases; Dinoprost; Epoprostenol; Female; Placenta; Pregnancy; Prostaglandins F; Puerperal Disorders; Radioimmunoassay; Time Factors

Topics: Dinoprost; Female; Humans; Magnesium Sulfate; Pregnancy; Prostaglandins F; Puerperal Disorders; Terbutaline; Uterine Diseases; Uterus

Topics: Animals; Cattle; Cattle Diseases; Dinoprost; Estrogens; Female; Oxytocin; Pregnancy; Prostaglandins F; Puerperal Disorders

Topics: Animals; Cattle; Cattle Diseases; Dinoprost; Female; Ovarian Diseases; Ovary; Pituitary Hormone-Releasing Hormones; Postpartum Period; Pregnancy; Prostaglandins F; Puerperal Disorders

Topics: Animals; Dinoprost; Estradiol; Female; Hormones; Lactation; Luteinizing Hormone; Ovarian Cysts; Pregnancy; Progesterone; Prostaglandins F; Puerperal Disorders; Swine; Swine Diseases

Topics: Adult; Cesarean Section; Dinoprost; Electrocardiography; Female; Humans; Pregnancy; Propranolol; Prostaglandins F; Puerperal Disorders; Uterine Contraction; Wolff-Parkinson-White Syndrome